lifestyle.californiaconsumerbanking.com

Author: Artelo Biosciences

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

May 7, 2026
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

May 6, 2026
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

May 5, 2026
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 4, 2026
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 4, 2026
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

May 4, 2026
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

May 2, 2026
Artelo Biosciences Announces Reverse Stock Split

April 30, 2026
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

April 28, 2026